Member Info for Bananaman2

Pretty sure the 7 year revenue projection was $75m or roughly £60m per annum.

I am convinced that it will not take much for this business to start being profitable taking in to consideration overheads not just cost of sales.

The SP chart looks to have been scrapping along the bottom and now heading back up. Looking for 3p short term then 8 -10p within 6 - 8 months on confirmation of continued growth to give them a MCap of circa £30 - 40mln. Not unrealtsic for a company in this sector with this much potential.

Valuefinder. I am not sure how the companies you mention stack up in respect of product range, revenues etc but they all have staggeringly larger MCaps than VAL. IMO this is where there is plenty of value left to be found.

Just watched the proactive video. Seems ITX are at a very exciting transition with the business. Revenue is expected to be greater than 100% increase on last year, 2021 doubling that whilst 2023 they are anticipating $25m. This is estimated based upon sending of samples to customers which typically take 2 - 4 years to transition to products.

Driving growth with existing products whilst developing new ranges. Customers growth towards personal care also growing.

No major capital spend requirements required. The facility has $mlns of dollars per annum growth potential. Huge addressable market >$300mln per year.

ITX have protected the polymers and are the only manufacturer in the world as such.

£7m MCap in a market worth £bn's. Capital investments made, cash in the bank and an exponential growth rate of revenue. Each increase is closer to medium term target of break even and will present an increase in margin.

Exciting turn around. Great to see a company get beyond the initial stages of breaking into the market.

it was done over 10 days ago.

from the 8th January RNS and protected until 2037

Itaconix receives new patent for detergent compositions

Itaconix (LSE: ITX) (OTCQB: ITXXF), a leading innovator in sustainable specialty polymers, is pleased to announce that the US Patent and Trademark Office has formally issued a new patent to the Company for the composition of detergents containing Itaconix's novel bio-based polymers.

This new patent provides the Company an additional layer of intellectual property protection for the unique value of Itaconix polymers in non-phosphate automatic dishwashing detergents. In addition, the new patent extends the Company's proprietary position in key detergent compositions to 2037

What is interesting is the IP and the value just in that. I would expect the patents would be worth more than the MCap. Especially to a major organisation using the products for one of their lines.

Wololol. There is significant value in ITX products, big companies such as P&G, Croda etc are finding or may find uses for them as regulation changes and substances are banned.

Wow. Yeah, I bet there are a number of companies out there in the sector that make zero revenue but have a much larger MCap.

That is what makes this quite an exciting proposition. Potentially lots of value at this level to be comparable to sector peers. As the business grows once the disparity gap is closed so will the MCap grow (and the SP)

https://www.proactiveinvestors.co.uk/companies/amp/news/925070

Statements from the CEO like this are interesting

' I am particularly encouraged by our progress at converting our detergent project pipeline with aggregate annual revenue potential of $20 million into new customer product launches, including the volumes under the New Wave detergent polymer agreement. Our revenue opportunities are expanding, and we look forward to the future with growing confidence."

Huge growth potential over current revenue for just the detergent project pipeline.

Revenue can also be generated from personal care and industrial sectors.

Every business has to go through the development phase. From what I can see and where ITX are now in comparison to a few years ago are very different positions. The current version of ITX has sufficient capital to see them through tonthe end of 2021 whilst they have been working with some major organisations and have gained acceptance for their products. This is a stark contrast to where they were 2 to 3 years ago.

Sentiment seems to be changing in investors. There are similar stories currently playing out on AIM. Investors are right to be cautious especially whe they have been here for several years. Fully agree.

Genuinely excited to see how this develops and feel that we could be looking great business here. There are several scenarios but let's just see how they get on as they are before anything is considered.

The next stop should be 3p. It may be sooner rather than later.

There are plenty of companies on AIM that don't generate any revenue with much higher MCaps and no sign of turning a profit.

I can see ITX getting there whilst continuing to expand the product range and industry uses.

RB, now we have all that bad news and history out the way, a recent placing to raise funds seeing them through to late 2021 when they are aiming to be closer to their medium target of break even.

The growth rate over the last 2 years has been exponential. Up around 90% in the first 6 months from the first 6 months in 2019.

Big customer like Croda (£8bn MCap) will not just buy products without testing them. There must be several customers that ITX are working with in similar positions.

Thanks for your take and yes, buyer should always beware, having done a fair amount of research this weekend I was happy with where they are currently.

3p would not present a very generous MCap either. Circa £13m

With the exponential growth rate it is an exciting opportunity. I would be happy if the SP could get back towards 6p by the end of the year and 10p within 12 months.

Perhaps the trigger will be further contracts with big organisations. Looking at the clients, ITX seem to have been recognised by some fairly major organisations already.

Large volume will easily break 7m today. That's well over 10% of the company share capital. Very good as this has been consistent over the last week. Not just a spike on a one off high volume day.

Sheephatch, only just starting.

At 20p the fully diluted MCap is just £12m. Still under half of sector peers with similarly advanced oncology related treatments.

Probably right Feeks, We should be comfortable with that. I don't think news of orders will ever be that far away with Verditek. 15 hungry sales staff selling a fantastic product in sectors which are crying out for change such as this.

Today will potentially be day 1 of 5 consecutives days with a 15p plus closing price required to trigger the warrants. Additional cash in the bank is not a bad thing by any ones standard. Dilutive effect is minimal and will only help sustain the business to progress the products at the advanced trial stages.

Added another 25k at 1.675. That's it for today. Fingers crossed that was also timed right.

Just ticked up. Was offered 1.6 to sell a small number and 1.55 for 150k.

Hoping I timed this just right. Thankfully it was very quiet this morning.

My buy will show here in 10m minutes as a sell. You watch !

Also shows as a sell on ADVFN as spread shown as 1.4 - 1.8.

Can only get 15000 still at 1.54. Still NT or Fill or Kill for anything bigger.